A recent study has reported that Parkinson’s can be distinguished from multiple system atrophy using new technology known as protein misfolding cyclic amplification.
Browsing: neurodegenerative disease
Activation of group 2 innate lymphoid cells has been demonstrated to reduce age-related cognitive decline in mice. They could represent a new therapeutic target for the treatment of neurocognitive diseases.
Researchers have developed an artificial intelligence algorithm that can identify molecular patterns specific to Alzheimer’s and Huntington’s disease. This study could lead to a more individualized approach to neurodegenerative disease treatment.
Artificial neurons have been developed in a first-of-its-kind achievement that closely resemble biological neurons, mimicking their responses to a range of stimulations.
Abstracts presented at SfN Neuroscience 2019 provide insight into how gene therapy advancements could be used treat diseases such as Parkinson’s and Alzheimer’s in the future.
What are the challenges surrounding clinical trial design for genetic therapies in terms of neurodegenerative diseases? What technological advances could help bring these therapies to the clinic more quickly? Find out in our video interview with Sarah Tabrizi.
Genetic therapies represent a remarkable avenue for potentially slowing and preventing neurodegenerative diseases. This includes a first-in-human, gene-silencing treatment for Alzheimer’s disease. Find out more on this from Catherine Mummery.
In this video, we spoke with Henrik Zetterberg to find out how challenges with replication, reproducibility and specificity could be addressed in the field.
Researchers have found that the sleep history and pattern of older men and women may predict the accumulation of proteins associated with Alzheimer’s disease.
To mark World Parkinson’s Day, we’re taking the opportunity to look back on some of the research highlights in the field over the last year.